The Quantellect read.As of Nov 19, 2026, 3 active firms cover Crescent Biopharma, Inc: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $27.00 to $36.00, so the covering firms are broadly aligned. The average target of $32.67 sits 163% above the current $12.41. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 2 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.65 next quarter toward $-3.07 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$32.67
+163.2% upside
Average target across 3 active firms as of Nov 19, 2026 vs $12.41 current
Highest Target$36.00
Average Target$32.67
Lowest Target$27.00
Detailed analyst forecasts for CBIO
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate CBIO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CBIO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.65
Range $-0.65 – $-0.65 · 1 analysts · -7% YoY
Next period, 1 analysts expect Crescent Biopharma, Inc. to earn $-0.65 a share (range $-0.65 – $-0.65), versus $-0.70 a year earlier. Full-year consensus is $-2.76, growing to $-3.07 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $4.3M, rising to $3.4M next year.
Top analysts covering Crescent Biopharma, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CBIO.
#1
Mitchell Kapoor
HC Wainwright & Co. · Rank #305
Buy
$36.00+190.1% to target
Overall win rate
33%
+ Follow
#2
SW
Stephen Willey
Stifel · Rank #474
Buy
$28.00+125.6% to target
Overall win rate
29%
+ Follow
#3
Robert Driscoll
Wedbush · Rank #490
Buy
$27.00+117.6% to target
Overall win rate
32%
+ Follow
#4
CZ
Charles Zhu
LifeSci Capital
Buy
$28.00+125.6% to target
Coverage
—
+ Follow
#5
Akash Tewari
Jefferies
Buy
$35.00+182.0% to target
Coverage
—
+ Follow
CBIO stock forecast FAQ
What is CBIO's average 12-month price target?+
The 3 active firms with a live target average $32.67 for Crescent Biopharma, Inc. over the next 12 months, ranging from a $36.00 high to a $27.00 low, as of Nov 19, 2026.
Is CBIO stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CBIO?+
The Street-high target is $36.00 (HC Wainwright & Co.), and the Street-low is $27.00 (Wedbush). The average of all 3 active-firm targets is $32.67.
How many active Wall Street firms cover CBIO?+
3 active firms have a recognized rating on Crescent Biopharma, Inc. as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CBIO?+
Among analysts who currently cover CBIO, Mitchell Kapoor of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #305). Their current call is Buy with a $36.00 target.
What is Crescent Biopharma, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.65 per share (range $-0.65 – $-0.65) across 1 analysts. Full-year EPS is projected at $-2.76, rising to $-3.07 the following year.
How much revenue is Crescent Biopharma, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $4.3M, growing to $3.4M next year.
Have analysts been upgrading or downgrading CBIO lately?+
As of Nov 19, 2026, 3 of 3 active firms rate CBIO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CBIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.